CRBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-12), Corbus Pharmaceuticals Holdings's share price is $42.99. Corbus Pharmaceuticals Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.42. Hence, Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:
Corbus Pharmaceuticals Holdings's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-1.36. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-8.42.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 39.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 19.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -24.80% per year.
During the past 11 years, Corbus Pharmaceuticals Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 39.90% per year. The lowest was -187.60% per year. And the median was -31.00% per year.
The historical data trend for Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Corbus Pharmaceuticals Holdings Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow falls into.
Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 42.99 | / | -8.417 | |
= | N/A |
Corbus Pharmaceuticals Holdings's Share Price of today is $42.99.
Corbus Pharmaceuticals Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Corbus Pharmaceuticals Holdings (NAS:CRBP) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Yong Ben | director | 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Anne Altmeyer | director | 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Yuval Cohen | director, officer: Chief Executive Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Craig Stuart Millian | officer: Chief Commercial Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Sean F. Moran | officer: Chief Financial Officer | 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046 |
Rachael Louise Brake | officer: Chief Scientific Officer | 21 MANCHESTER PLACE, NATICK MA 01760 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Peter Salzmann | director | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Barbara White | officer: Chief Medical Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Robert Paul Discordia | officer: Chief Operating Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
David P Hochman | director | 15 WESTON HILL RD., RIVERSIDE CT 06878 |
John Kenneth Jenkins | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Paris Panayiotopoulos | director | ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Alan F Holmer | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
From GuruFocus
By PRNewswire PRNewswire • 02-13-2023
By PRNewswire PRNewswire • 05-21-2022
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire PRNewswire • 06-09-2022
By PRNewswire PRNewswire • 07-09-2022
By PRNewswire PRNewswire • 04-17-2023
By Marketwired • 10-03-2023
By PRNewswire PRNewswire • 11-10-2022
By PRNewswire PRNewswire • 10-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.